logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Renal cancer: cabozantinib shows quality-adjusted survival benefit vs sunitinib

Post hoc analysis of phase 2 CABOSUN trial.